Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF10 Entecavir
D04008 Entecavir (USP) <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-hepatitis B (HBV) Agents
Entecavir
D04008 Entecavir (USP)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D04008 Entecavir (USP); Entecavir hydrate (JAN)
Drug groups [BR:br08330]
Antiviral
DG01890 Nucleoside reverse transcriptase inhibitor (NRTI)
DG00661 Entecavir
D04008 Entecavir
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HBV reverse transcriptase inhibitor
D04008 Entecavir (USP) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04008
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04008
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04008
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04008
Drug groups [BR:br08330]
Antiviral
DG01890 Nucleoside reverse transcriptase inhibitor (NRTI)
DG00661 Entecavir
Antimicrobials abbreviations [BR:br08327]
Antivirals
Genome replication inhibitor
HBV reverse transcriptase inhibitor
DG00661 Entecavir